Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxycodone vaccine
- Development stage
- Unknown
- Lead developer
- University of Washington
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The oxycodone vaccine (specifically Oxy(Gly)4-sKLH) is an investigational conjugate vaccine designed to treat opioid use disorder (OUD) and prevent oxycodone-induced overdose. Developed by researchers at the University of Minnesota and the University of Washington, and licensed to CounterX Therapeutics, the vaccine consists of an oxycodone-based hapten conjugated to the subunit keyhole limpet hemocyanin (sKLH) carrier protein via a tetraglycine linker. It works by stimulating the production of oxycodone-specific polyclonal IgG antibodies that sequester the drug in the bloodstream, preventing it from crossing the blood-brain barrier and entering the central nervous system. This blocks the euphoric, analgesic, and respiratory-depressant effects of oxycodone without interfering with other medications used in opioid use disorder treatment (such as methadone, buprenorphine, naltrexone, or naloxone). The vaccine is currently being evaluated in a Phase 1/2 clinical trial.
- Other names
- OXY-sKLHOXY-sKLH vaccineOxy(Gly)4-sKLHOxy(Gly)4-sKLH Conjugate VaccineOxy(Gly)4-sKLH Conjugate Vaccine, AdsorbedOxycodone VaccineOxycodone-sKLH vaccine
Beyond the preview
Go deeper on oxycodone vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxycodone vaccine.